Comparing Immunotherapy with Standard Chemotherapy for Lung Cancer After Surgery
NCT04267848 · RecruitingThis clinical trial is looking at how well adding a drug called pembrolizumab works with standard chemotherapy for patients with non-small cell lung cancer. This cancer has been surgically removed and is in stages IIA, IIB, IIIA, or IIIB. The goal is to see if this combination can help improve outcomes for patients after surgery.
Locations and contact
This trial is running at 1,150 locations. The first 8 are listed here.
- Anchorage Associates in Radiation MedicineAnchorage, AlaskaSuspended
- Anchorage Radiation Therapy CenterAnchorage, AlaskaSuspended
- Alaska Breast Care and Surgery LLCAnchorage, AlaskaSuspended
- Alaska Oncology and Hematology LLCAnchorage, AlaskaSuspended
- Alaska Women's Cancer CareAnchorage, AlaskaSuspended
- Anchorage Oncology CentreAnchorage, AlaskaSuspended
- Katmai Oncology GroupAnchorage, AlaskaRecruiting
- Providence Alaska Medical CenterAnchorage, AlaskaSuspended
Who can join
This study is for men and women aged 18 and older. Participants must have completely removed stage IIA, IIB, IIIA, or IIIB non-small cell lung cancer. They should not have had previous treatment for this cancer or certain other health issues. The trial team will confirm who can join.
What happens during the trial
Participants are randomly placed into one of two groups. One group receives standard chemotherapy followed by pembrolizumab. The other group receives the same chemotherapy but with pembrolizumab given together. All participants will also have regular check-ups and tests during the trial.
The trial team
The trial is sponsored by the National Cancer Institute. The principal investigator is Dr. Jacob M Sands from the Alliance for Clinical Trials in Oncology.
Important dates
The trial started on June 16, 2020, and is expected to finish by January 31, 2027. It is currently enrolling new participants.
Additional information
The trial ID is NCT04267848. This is a Phase 3 trial, which means it's testing how well the treatment works and its safety. It is FDA-regulated and aims to include about 1210 participants.
Other recruiting trials for the same condition, with the eligibility rules written in plain language.
Browse similar trials →Find a top oncologist who can tell you whether a trial is a sensible option for you.
Find a doctor →The cancer centers running studies like this one, and what each is known for.
Browse hospitals →